West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Accra, Ghana.
Navrongo Health Research Centre, Ghana Health Service, P. O. Box 114, Navrongo, Ghana.
Malar J. 2021 Mar 17;20(1):152. doi: 10.1186/s12936-021-03693-3.
Anti-malarial drug resistance remains a key concern for the global fight against malaria. In Ghana sulfadoxine-pyrimethamine (SP) is used for intermittent preventive treatment of malaria in pregnancy and combined with amodiaquine for Seasonal Malaria Chemoprevention (SMC) during the high malaria season. Thus, surveillance of molecular markers of SP resistance is important to guide decision-making for these interventions in Ghana.
A total of 4469 samples from uncomplicated malaria patients collected from 2009 to 2018 was submitted to the Wellcome Trust Sanger Institute, UK for DNA sequencing using MiSeq. Genotypes were successfully translated into haplotypes in 2694 and 846 mono infections respectively for pfdhfr and pfdhps genes and the combined pfhdfr/pfdhps genes across all years.
At the pfdhfr locus, a consistently high (> 60%) prevalence of parasites carrying triple mutants (IRNI) were detected from 2009 to 2018. Two double mutant haplotypes (NRNI and ICNI) were found, with haplotype NRNI having a much higher prevalence (average 13.8%) than ICNI (average 3.2%) across all years. Six pfdhps haplotypes were detected. Of these, prevalence of five fluctuated in a downward trend over time from 2009 to 2018, except a pfdhps double mutant (AGKAA), which increased consistently from 2.5% in 2009 to 78.2% in 2018. Across both genes, pfdhfr/pfdhps combined triple (NRNI + AAKAA) mutants were only detected in 2009, 2014, 2015 and 2018, prevalence of which fluctuated between 3.5 and 5.5%. The combined quadruple (IRNI + AAKAA) genotype increased in prevalence from 19.3% in 2009 to 87.5% in 2011 before fluctuating downwards to 19.6% in 2018 with an average prevalence of 37.4% within the nine years. Prevalence of parasites carrying the quintuple (IRNI + AGKAA or SGEAA) mutant haplotypes, which are highly refractory to SP increased over time from 14.0% in 2009 to 89.0% in 2016 before decreasing to 78.9 and 76.6% in 2017 and 2018 respectively. Though quintuple mutants are rising in prevalence in both malaria seasons, together these combined genotypes vary significantly within season but not between seasons.
Despite high prevalence of pfdhfr triple mutants and combined pfdhfr/pfdhps quadruple and quintuple mutants in this setting SP may still be efficacious. These findings are significant as they highlight the need to continuously monitor SP resistance, particularly using deep targeted sequencing to ascertain changing resistance patterns.
抗疟药物耐药性仍然是全球抗击疟疾的一个关键问题。在加纳,磺胺多辛-乙胺嘧啶(SP)用于孕妇间歇性预防治疗疟疾,并在高疟疾季节与阿莫地喹联合用于季节性疟疾化学预防(SMC)。因此,监测 SP 耐药的分子标志物对于指导加纳的这些干预措施的决策非常重要。
从 2009 年至 2018 年收集的来自非复杂性疟疾患者的 4469 个样本被提交给英国 Wellcome Trust Sanger 研究所,用于使用 MiSeq 进行 DNA 测序。在所有年份中,成功地将 2694 个和 846 个单感染的 pfdhfr 和 pfdhps 基因的基因型分别转化为单倍型,以及合并的 pfhdfr/pfdhps 基因。
在 pfdhfr 基因座上,从 2009 年到 2018 年,一直检测到携带三重突变体(IRNI)的寄生虫的高比例(>60%)。发现了两种双突变体单倍型(NRNI 和 ICNI),NRNI 单倍型的流行率(所有年份的平均 13.8%)明显高于 ICNI(平均 3.2%)。检测到六种 pfdhps 单倍型。其中,除了 pfdhps 双突变体(AGKAA)外,五种的流行率在 2009 年至 2018 年间呈下降趋势,该双突变体的流行率从 2009 年的 2.5%增加到 2018 年的 78.2%。在这两个基因中,pfdhfr/pfdhps 联合三重(NRNI+AAKAA)突变体仅在 2009 年、2014 年、2015 年和 2018 年检测到,其流行率在 3.5%至 5.5%之间波动。联合四重(IRNI+AAKAA)基因型的流行率从 2009 年的 19.3%增加到 2011 年的 87.5%,然后波动下降到 2018 年的 19.6%,在九年期间的平均流行率为 37.4%。携带 SP 高度耐药的五重突变体(IRNI+AGKAA 或 SGEAA)单倍型的寄生虫流行率随着时间的推移而增加,从 2009 年的 14.0%增加到 2016 年的 89.0%,然后在 2017 年和 2018 年分别下降到 78.9%和 76.6%。尽管在两个疟疾季节中五重突变体的流行率都在上升,但这些联合基因型在季节内变化显著,但在季节之间没有变化。
尽管在这一环境中存在高比例的 pfdhfr 三重突变体和联合的 pfdhfr/pfdhps 四重体和五重体突变体,但 SP 可能仍然有效。这些发现意义重大,因为它们强调了需要持续监测 SP 耐药性,特别是使用深度靶向测序来确定不断变化的耐药模式。